HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Severe hyperlipoproteinemia in congenital nephrotic syndrome of the Finnish type: effect of dialysis and kidney transplantation.

Abstract
Two children with congenital nephrosis of the Finnish type were studied successively at the three stages of the disease: (A) nephrosis, (B) renal insufficiency/peritoneal dialysis and (C) post-transplantation; two additional patients were studied at two stages. Plasma lipoprotein profiles were determined by density gradient ultracentrifugation and lipids by enzymatic methods. Stage A was characterized by hyperchylomicronemia, low high density lipoprotein (HDL) cholesterol and the presence of dense low density lipoprotein (LDL) and HDL particles. Total cholesterol and triglycerides showed great daily variation (5-14 and 5-33 mmol/l, respectively). During stage B, hyperlipidemia weakened. Yet HDL concentration remained low and the concentration of intermediate density lipoproteins (IDL) increased. At stage C, hyperlipidemia had almost subsided, but the presence of IDL persisted. In conclusion, severe hyperlipoproteinemia of congenital nephrosis at the nephrotic stage is attenuated during renal insufficiency and dialysis, and essentially normalizes after kidney transplantation. Yet the presence of IDL implies an increased risk of atherosclerosis.
AuthorsM K Salo, O Jaakkola, T Solakivi, S Ylä-Herttuala
JournalActa paediatrica (Oslo, Norway : 1992) (Acta Paediatr) Vol. 82 Issue 9 Pg. 768-72 (Sep 1993) ISSN: 0803-5253 [Print] Norway
PMID8241675 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Arteriosclerosis (etiology)
  • Female
  • Humans
  • Hyperlipoproteinemias (blood, etiology)
  • Infant
  • Infant, Newborn
  • Kidney Transplantation
  • Male
  • Nephrotic Syndrome (complications, congenital, therapy)
  • Peritoneal Dialysis
  • Risk

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: